G. Lopez‐Berestein
- Infectious Diseases top 5%
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery 4
- Pharmaceutical Science top 5%
-
- Immunotherapy and Immune Responses 2
-
- CAR-T cell therapy research 3
-
- RNA Interference and Gene Delivery 8
- DNA and Nucleic Acid Chemistry 4
- Retinoids in leukemia and cellular processes 4
- Cell death mechanisms and regulation 2
-
- Monoclonal and Polyclonal Antibodies Research 3
- Co-authors
- Bülent ÖzpolatAnil K. SoodDavid R. LukeKiumars VadieiR. L. JulianoKapil MehtaMichael G. RosenblumE. M. Hersh
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
G. Lopez‐Berestein
36 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 96
- Infectious Diseases 267
- Biomaterials 150
- Pharmaceutical Science 59
- Immunology 178
- Oncology 222
Countries citing papers authored by G. Lopez‐Berestein
This map shows the geographic impact of G. Lopez‐Berestein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Lopez‐Berestein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Lopez‐Berestein more than expected).
Fields of papers citing papers by G. Lopez‐Berestein
This network shows the impact of papers produced by G. Lopez‐Berestein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Lopez‐Berestein. The network helps show where G. Lopez‐Berestein may publish in the future.
Co-authorship network
The 25 scholars most cited alongside G. Lopez‐Berestein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2018 | 1 | |
| 3 | The RNA-binding protein LARP1 is a cancer therapeutic target | 2017 | 1 |
| 4 | 2015 | 26 | |
| 5 | 2015 | 2 | |
| 6 | 2009 | 177 | |
| 7 | 2005 | 28 | |
| 8 | 2004 | 1 | |
| 9 | 2002 | 32 | |
| 10 | 1998 | 33 | |
| 11 | 1997 | 21 | |
| 12 | 1996 | 57 | |
| 13 | Antisense oligonucleotides and carriers for gene therapy | 1993 | 4 |
| 14 | 1992 | 88 | |
| 15 | 1991 | 7 | |
| 16 | Tumor necrosis factor and c-fos expression in human peripheral-blood monocytes: expression is dependent on stage of in vitro differentiation. | 1991 | 1 |
| 17 | 1990 | 69 | |
| 18 | Prospects for liposomes as a novel drug delivery system | 1985 | 0 |
| 19 | New lives for old drugs: Liposomal drug delivery systems reduce the toxicity but not the potency of certain chemotherapeutic agents | 1985 | 7 |
| 20 | Tumor cytotoxicity of human peripheral blood monocytes activated by muramyl dipeptide analogues | 1982 | 1 |
About G. Lopez‐Berestein
G. Lopez‐Berestein is a scholar working on Transplantation, Hematology and Biomaterials, having authored 38 papers that have together received 1.3k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (8 papers), Nanoparticle-Based Drug Delivery (4 papers), DNA and Nucleic Acid Chemistry (4 papers), Retinoids in leukemia and cellular processes (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), CAR-T cell therapy research (3 papers), Cell death mechanisms and regulation (2 papers) and Immunotherapy and Immune Responses (2 papers). The work is most often cited by research in Infectious Diseases (267 citations), Biomaterials (150 citations) and Pharmaceutical Science (59 citations). G. Lopez‐Berestein has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Bülent Özpolat, Anil K. Sood, David R. Luke, Kiumars Vadiei, R. L. Juliano, Kapil Mehta, Michael G. Rosenblum, E. M. Hersh, James M. Reuben and M. P. Sullivan. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.